蘭衞醫學(301060.SZ)2021年度淨利潤預增68.51%-106.57%
格隆匯1月26日丨蘭衞醫學(301060.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤1.86億元-2.28億元,同比增長68.51%-106.57%;扣除非經常性損益後的淨利潤1.65億元-2.1億元,同比增長56.32%-98.95%。業績變動原因如下:
1. 公司作為一家為檢驗診斷行業提供整體解決方案的綜合服務商,依託不斷升級的“產品+服務”的商業模式,面向各級醫療機構提供第三方醫學檢驗和病理診斷服務、國內外知名品牌體外診斷產品以及其他專業技術支持,以滿足各級醫療機構的差異化需求。
報吿期內,由於疫情好轉,公司醫學診斷服務和體外診斷產品銷售收入較同期均有所增長。
2. 報吿期內,公司積極參與國家新冠疫情聯防聯控工作,踐行企業社會責任:公司依託品牌化、規模化、標準化的實驗室網絡,以中心實驗室與方艙實驗室為載體,組織專業團隊參與了湖北、廣東、江蘇、湖南、福建、陝西等多省份、多個地區的新冠核酸篩查,核酸檢測收入有較大增幅。
3.報吿期內,預計非經常損益對淨利潤的影響金額範圍1600萬元-2400萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.